Bladder Cancer at a Crossroads: Sequencing, Biomarkers, and Combination Therapy

Bladder Cancer, Non-Muscle Invasive (NMIBC) /

Multiple new NMIBC therapies offer bladder preservation hope: cretostimogene shows 46% 1-year response with minimal toxicity.

Bladder Cancer at a Crossroads: Sequencing, Biomarkers, and Combination Therapy Read More ยป